Treatment of osteoarthritis in hypertensive patients

Mackenzie, Isla S.; MacDonald, Thomas M.

doi:10.1517/14656560903496422

Cited by 21 publications

(17 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this group of patients interactions with clinical significance C were identified in 97.9%, D in 20.4%, and X in 0.8% patients. The median number of clinically significant potential drug interactions per patient was 4 (range, [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19], of interactions with clinical significance C 4 (range, 1-15), D 1 (range, 1-6), and X 1 (range, 1-1). We identified 215 drug combinations with potential to cause clinically significant drug interaction (Table 3).…”

Section: Resultsmentioning

confidence: 99%

“…It is well known that NSAID can increase blood pressure and interfere with lowering effect of many classes of antihypertensive drugs. Even small rises in blood pressure due to therapy with NSAID may significantly increase cardiovascular risk, if sustained over a long time [19,20]. According to the published data, interaction between NSAID and cardiovascular drugs are the most common interactions in the elderly associated with adverse patient outcomes [21,22].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The incidence of potential drug–drug interactions in elderly patients with arterial hypertension

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The incidence of potential drug–drug interactions in elderly patients with arterial hypertension

et al. 2010

View full text Add to dashboard Cite

show abstract

“…We then excluded participants who used non-steroidal anti-inflammatory drugs (NSAIDs) (n = 439), which are known to increase BP. 12–15 Finally, to mitigate against the common bias in pharmacoepidemiology that sicker patients are generally treated with more potent therapy (e.g., increased dosage or number of drugs), 16 we excluded all participants who used antihypertensive medications during 30 days before the 48 month visit (n = 679). After these exclusions, 707 adults contributed to the analytic sample.…”

Section: Methodsmentioning

confidence: 99%

Sedentary behavior and blood pressure control among osteoarthritis initiative participants

Sohn

Manheim

Chang

et al. 2014

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

OBJECTIVE To examine the association between sedentary behavior and BP among Osteoarthritis Initiative (OAI) participants. DESIGN We conducted a cross-sectional analysis of the OAI 48-month visit participants whose physical activity was measured using accelerometers. Participants were classified into four quartiles according to the percentage of wear time that was sedentary (<100 activity counts per minute). Users of antihypertensive medications or NSAIDs were excluded. Our main outcomes were systolic and diastolic blood pressures (SBP and DBP) and “elevated BP” defined as BP ≥ 130/85 mm Hg. RESULTS For this study cohort (N = 707), mean BP was 121.4 ± 15.6/74.7 ± 9.5 mm Hg and 33% had elevated BP. SBP had a graded association with increased sedentary time (P for trend = 0.02). The most sedentary quartile had 4.26 mm Hg higher SBP (95% CI, 0.69 – 7.82; p = 0.02) than the least sedentary quartile, adjusting for age, moderate-to-vigorous (MV) physical activity, and other demographic and health factors. The probability of having elevated BP significantly increased in higher sedentary quartiles (P for trend = 0.046). There were no significant findings for DBP. CONCLUSION A strong graded association was demonstrated between sedentary behavior and increased SBP and elevated BP, independent of time spent in MV physical activity. Reducing daily sedentary time may lead to improvement in blood pressure and reduction in cardiovascular risk.

show abstract

“…We will therefore perform pairwise comparisons of conditions to assess numbers of patients who have interactions within their prescribed medications. [39][40][41][42][43][44][45][46][47][48][49][50][51][52][53] This will allow us to determine which combinations of conditions are most frequently associated with polypharmacy. For this work we are defining multimorbidity as having two or more of our target conditions diagnosed with an active Read Code.…”

Section: Prevalence Of Multimorbiditymentioning

confidence: 99%

Assessing the extent of drug interactions among patients with multimorbidity in primary and secondary care in the West Midlands (UK): a study protocol for the Mixed Methods Multimorbidity Study (MiMMS)

Backman

Weber

Turner³

et al. 2017

BMJ Open

View full text Add to dashboard Cite

IntroductionThe numbers of patients with three or more chronic conditions (multimorbidity) are increasing, and will rise to 2.9 million by 2018 in the UK alone. Currently in the UK, conditions are mainly managed using over 250 sets of single-condition guidance, which has the potential to generate conflicting recommendations for lifestyle and concurrent medication for individual patients with more than one condition. To address some of these issues, we are developing a new computer-based tool to help manage these patients more effectively. For this tool to be applicable and relevant to current practice, we must first better understand how existing patients with multimorbidity are being managed, particularly relating to concerns over prescribing and potential polypharmacy.Methods and analysisUp to four secondary care centres, two community pharmacies and between four and eight primary care centres in the West Midlands will be recruited. Interviewees will be purposively sampled from these sites, up to a maximum of 30. In this mixed methods study, we will perform a dual framework analysis on the qualitative data; the first analysis will use the Theoretical Domains Framework to assess barriers and enablers for healthcare professionals around the management of multimorbid patients; the second analysis will use Normalisation Process Theory to understand how interventions are currently being successfully implemented in both settings. We will also extract quantitative anonymised patient data from primary care to determine the extent of polypharmacy currently present for patients with multimorbidity in the West Midlands.DiscussionWe aim to combine these data so that we can build a useful, fully implementable tool which addresses the barriers most amenable to change within both primary and secondary care contexts.Ethics and disseminationFavourable ethical approval has been granted by The University of Birmingham Research Ethics Committee (ERN_16–0074) on 17 May 2016. Our work will be disseminated through peer-reviewed literature, trade journals and conferences. We will also use the dedicated web page hosted by the University to serve as a central point of contact and as a repository of our findings. We aim to produce a minimum of three articles from this work to contribute to the international scientific literature.Protocol registration numberNIHR Clinical Research Network Portfolio Registration CPMS ID 30613.

show abstract

Treatment of osteoarthritis in hypertensive patients

Abstract: There are ways to minimise the adverse impact of treatment of osteoarthritis on blood pressure control in hypertensive patients.

Cited by 21 publications

References 56 publications

The incidence of potential drug–drug interactions in elderly patients with arterial hypertension

The incidence of potential drug–drug interactions in elderly patients with arterial hypertension

Sedentary behavior and blood pressure control among osteoarthritis initiative participants

Assessing the extent of drug interactions among patients with multimorbidity in primary and secondary care in the West Midlands (UK): a study protocol for the Mixed Methods Multimorbidity Study (MiMMS)

Contact Info

Product

Resources

About